. "2581749-86-0" . . . . . . . . . "Rx-only"@en . . . . "Ervebo, Zabdeno, Mvabea"@en . . . . . . . . . . . "Ein Ebola-Impfstoff ist ein Impfstoff gegen das Ebolavirus."@de . . "Vaksin ebola adalah vaksin yang dikembangkan untuk mencegah . Vaksin ebola pertama yang mendapatkan izin penggunaan dari Badan Pengawas Obat dan Makanan Amerika Serikat adalah rVSV-ZEBOV pada Desember 2019. Vaksin ini digunakan untuk menanggulangi berdasarkan protokol ."@in . . . . . . . "Vaksin ebola"@in . "Vaccin contre le virus Ebola"@fr . . . "Ein Ebola-Impfstoff ist ein Impfstoff gegen das Ebolavirus."@de . . . . . . "2581749"^^ . "BX02"@en . . . . . . . . . . . . . "Las vacunas contra el \u00C9bola son vacunas aprobadas o en desarrollo para prevenir el virus \u00E9bola. La primera vacuna aprobada en los Estados Unidos fue rVSV-ZEBOV en diciembre de 2019.\u200B\u200B Se hab\u00EDa utilizado ampliamente en la epidemia de \u00C9bola de Kivu bajo un protocolo de uso compasivoa principios del siglo XXI, varias vacunas candidatas demostraron eficacia para proteger primates no humanos (generalmente monos) contra infecciones letales. Las vacunas incluyen vectores de adenovirus de replicaci\u00F3n deficiente, estomatitis vesicular de replicaci\u00F3n competente (VSV) y parainfluenza humana (HPIV-3), y preparaciones de nanopart\u00EDculas similares a virus. Los ensayos convencionales para estudiar la eficacia mediante la exposici\u00F3n de seres humanos al pat\u00F3geno despu\u00E9s de la inmunizaci\u00F3n no son \u00E9ticos en este caso. Para tales situaciones, la Administraci\u00F3n de Drogas y Alimentos de los Estados Unidos (FDA) ha establecido la \"regla de eficacia animal\" que permite aprobar la licencia sobre la base de estudios de modelos animales que replican enfermedades humanas, combinados con pruebas de seguridad y una respuesta inmune potencialmente potente (anticuerpos en la sangre) de humanos que recibieron la vacuna. Los ensayos cl\u00EDnicos implican la administraci\u00F3n de la vacuna a sujetos humanos sanos para evaluar la respuesta inmunitaria, identificar cualquier efecto secundario y determinar la dosis adecuada."@es . "vaccine"@en . . . . . . . . . "1117050600"^^ . . . . . . . . . . . . . . . "Candidate Ebola vaccine being given"@en . "J07"@en . . . . . . . . "Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates (usually macaques) against lethal infection. Vaccines include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis (VSV) and human parainfluenza (HPIV-3) vectors, and virus-like nanoparticle preparations. Conventional trials to study efficacy by exposure of humans to the pathogen after immunization are not ethical in this case. For such situations, the US Food and Drug Administration (FDA) has established the \"animal efficacy rule\" allowing licensure to be approved on the basis of animal model studies that replicate human disease, combined with evidence of safety and a potentially potent immune response (antibodies in the blood) from humans given the vaccine. Clinical trials involve the administration of the vaccine to healthy human subjects to evaluate the immune response, identify any side effects and determine the appropriate dosage."@en . . . . . "Ebola vaccine"@en . . . . . "60202"^^ . "Ervebo, Zabdeno, Mvabea"@en . . . . "Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates (usually macaques) against lethal infection."@en . "Vaksin ebola adalah vaksin yang dikembangkan untuk mencegah . Vaksin ebola pertama yang mendapatkan izin penggunaan dari Badan Pengawas Obat dan Makanan Amerika Serikat adalah rVSV-ZEBOV pada Desember 2019. Vaksin ini digunakan untuk menanggulangi berdasarkan protokol ."@in . . "Vacunas contra el \u00C9bola"@es . . "Las vacunas contra el \u00C9bola son vacunas aprobadas o en desarrollo para prevenir el virus \u00E9bola. La primera vacuna aprobada en los Estados Unidos fue rVSV-ZEBOV en diciembre de 2019.\u200B\u200B Se hab\u00EDa utilizado ampliamente en la epidemia de \u00C9bola de Kivu bajo un protocolo de uso compasivoa principios del siglo XXI, varias vacunas candidatas demostraron eficacia para proteger primates no humanos (generalmente monos) contra infecciones letales."@es . . . "\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627 \u0647\u064A \u0644\u0642\u0627\u062D\u0627\u062A \u0625\u0645\u0627 \u0645\u0639\u062A\u0645\u062F\u0629 \u0623\u0648 \u0642\u064A\u062F \u0627\u0644\u062A\u0637\u0648\u064A\u0631 \u0644\u0644\u0648\u0642\u0627\u064A\u0629 \u0645\u0646 \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627. \u0627\u0639\u062A\u064F\u0645\u062F \u0623\u0648\u0644 \u0644\u0642\u0627\u062D \u0641\u064A \u0627\u0644\u0648\u0644\u0627\u064A\u0627\u062A \u0627\u0644\u0645\u062A\u062D\u062F\u0629 (\u0647\u0648 rVSV-ZEBOV) \u0641\u064A \u062F\u064A\u0633\u0645\u0628\u0631 2019. \u0648\u0627\u0633\u062A\u064F\u062E\u062F\u0645 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639 \u0623\u062B\u0646\u0627\u0621 \u062A\u0641\u0634\u064A \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627 \u0641\u064A \u0643\u064A\u0641\u0648 \u0628\u0645\u0648\u062C\u0628 \u0628\u0631\u0648\u062A\u0648\u0643\u0648\u0644 \u0627\u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0627\u0644\u0631\u062D\u064A\u0645. \u062E\u0644\u0627\u0644 \u0623\u0648\u0627\u0626\u0644 \u0627\u0644\u0642\u0631\u0646 \u0627\u0644\u062D\u0627\u062F\u064A \u0648\u0627\u0644\u0639\u0634\u0631\u064A\u0646\u060C \u0623\u0638\u0647\u0631 \u0627\u0644\u0639\u062F\u064A\u062F \u0645\u0646 \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0631\u0634\u062D\u0629 \u0641\u0639\u0627\u0644\u064A\u0629 \u0641\u064A \u0648\u0642\u0627\u064A\u0629 \u0627\u0644\u0631\u0626\u064A\u0633\u064A\u0627\u062A \u063A\u064A\u0631 \u0627\u0644\u0628\u0634\u0631\u064A\u0629 (\u0642\u0631\u0648\u062F \u0627\u0644\u0645\u0643\u0627\u0643 \u0639\u0627\u062F\u0629\u064B) \u0645\u0646 \u0627\u0644\u0639\u062F\u0648\u0649 \u0627\u0644\u0645\u0645\u064A\u062A\u0629. \u062A\u0634\u0645\u0644 \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0646\u0627\u0642\u0644\u0627\u062A \u0627\u0644\u0641\u064A\u0631\u0648\u0633 \u0627\u0644\u063A\u062F\u064A \u0646\u0627\u0642\u0635\u0629 \u0627\u0644\u0646\u0633\u062E \u0627\u0644\u0645\u062A\u0645\u0627\u062B\u0644\u060C \u0648\u0641\u064A\u0631\u0648\u0633 \u0627\u0644\u062A\u0647\u0627\u0628 \u0627\u0644\u0641\u0645 \u0627\u0644\u062D\u0648\u064A\u0635\u0644\u064A\u060C \u0648\u0641\u064A\u0631\u0648\u0633\u0627\u062A \u0646\u0638\u064A\u0631 \u0627\u0644\u0625\u0646\u0641\u0644\u0648\u0646\u0632\u0627 \u0627\u0644\u0628\u0634\u0631\u064A\u0629 (HPIV-3)\u060C \u0648\u0627\u0644\u0641\u064A\u0631\u0648\u0633\u0627\u062A \u0627\u0644\u0634\u0628\u064A\u0647\u0629 \u0628\u0627\u0644\u062C\u0633\u064A\u0645\u0627\u062A \u0627\u0644\u0646\u0627\u0646\u0648\u064A\u0629. \u0627\u0644\u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u062A\u0642\u0644\u064A\u062F\u064A\u0629 \u0644\u062F\u0631\u0627\u0633\u0629 \u0627\u0644\u0641\u0639\u0627\u0644\u064A\u0629 \u0639\u0646 \u0637\u0631\u064A\u0642 \u062A\u0639\u0631\u0636 \u0627\u0644\u0628\u0634\u0631 \u0644\u0645\u0633\u0628\u0628\u0627\u062A \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0628\u0639\u062F \u0627\u0644\u062A\u0645\u0646\u064A\u0639 \u0644\u064A\u0633\u062A \u0623\u062E\u0644\u0627\u0642\u064A\u0629 \u0641\u064A \u0647\u0630\u0647 \u0627\u0644\u062D\u0627\u0644\u0629. \u0641\u064A \u0645\u062B\u0644 \u0647\u0630\u0647 \u0627\u0644\u062D\u0627\u0644\u0627\u062A\u060C \u0623\u0646\u0634\u0623\u062A \u0625\u062F\u0627\u0631\u0629 \u0627\u0644\u063A\u0630\u0627\u0621 \u0648\u0627\u0644\u062F\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u00AB\u0642\u0627\u0639\u062F\u0629 \u0627\u0644\u0641\u0639\u0627\u0644\u064A\u0629 \u0639\u0646\u062F \u0627\u0644\u062D\u064A\u0648\u0627\u0646\u00BB \u0627\u0644\u062A\u064A \u062A\u0633\u0645\u062D \u0628\u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 \u0627\u0644\u062A\u0631\u062E\u064A\u0635 \u0639\u0644\u0649 \u0623\u0633\u0627\u0633 \u0627\u0644\u062F\u0631\u0627\u0633\u0627\u062A \u0627\u0644\u062A\u064A \u0623\u062C\u0631\u064A\u062A \u0639\u0644\u0649 \u0627\u0644\u0646\u0645\u0627\u0630\u062C \u0627\u0644\u062D\u064A\u0648\u0627\u0646\u064A\u0629 \u0627\u0644\u062A\u064A \u062A\u0634\u0628\u0647 \u0627\u0644\u0625\u0635\u0627\u0628\u0627\u062A \u0639\u0646\u062F\u0647\u0627 \u0627\u0644\u0625\u0635\u0627\u0628\u0627\u062A \u0627\u0644\u0628\u0634\u0631\u064A\u0629\u060C \u0645\u0639 \u0627\u0644\u0623\u062F\u0644\u0629 \u0627\u0644\u062A\u064A \u062A\u0624\u0643\u062F \u0639\u0644\u0649 \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0648\u0627\u0644\u0627\u0633\u062A\u062C\u0627\u0628\u0629 \u0627\u0644\u0645\u0646\u0627\u0639\u064A\u0629 \u0627\u0644\u0642\u0648\u064A\u0629 \u0627\u0644\u0645\u062D\u062A\u0645\u0644\u0629 (\u0648\u062C\u0648\u062F \u0627\u0644\u0623\u062C\u0633\u0627\u0645 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0641\u064A \u0627\u0644\u062F\u0645) \u0639\u0646\u062F \u0627\u0644\u0628\u0634\u0631 \u0627\u0644\u0630\u064A\u0646 \u0623\u0639\u0637\u0648\u0627 \u0627\u0644\u0644\u0642\u0627\u062D. \u062A\u062A\u0636\u0645\u0646 \u0627\u0644\u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064A\u0631\u064A\u0629 \u0625\u0639\u0637\u0627\u0621 \u0627\u0644\u0644\u0642\u0627\u062D \u0644\u0623\u0634\u062E\u0627\u0635 \u0623\u0635\u062D\u0627\u0621 \u0644\u062A\u0642\u064A\u064A\u0645 \u0627\u0644\u0627\u0633\u062A\u062C\u0627\u0628\u0629 \u0627\u0644\u0645\u0646\u0627\u0639\u064A\u0629 \u0648\u062A\u062D\u062F\u064A\u062F \u0623\u064A \u0622\u062B\u0627\u0631 \u062C\u0627\u0646\u0628\u064A\u0629 \u0648\u062A\u062D\u062F\u064A\u062F \u0627\u0644\u062C\u0631\u0639\u0629 \u0627\u0644\u0645\u0646\u0627\u0633\u0628\u0629."@ar . "Des vaccins contre le virus Ebola sont d\u00E9velopp\u00E9s depuis les ann\u00E9es 1980, mais leur emploi se heurte encore, quarante ans plus tard, \u00E0 diff\u00E9rents obstacles scientifiques et techniques."@fr . . . . . . . . . . . . . . . . . . . . "44003094"^^ . . . . . . "\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627 \u0647\u064A \u0644\u0642\u0627\u062D\u0627\u062A \u0625\u0645\u0627 \u0645\u0639\u062A\u0645\u062F\u0629 \u0623\u0648 \u0642\u064A\u062F \u0627\u0644\u062A\u0637\u0648\u064A\u0631 \u0644\u0644\u0648\u0642\u0627\u064A\u0629 \u0645\u0646 \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627. \u0627\u0639\u062A\u064F\u0645\u062F \u0623\u0648\u0644 \u0644\u0642\u0627\u062D \u0641\u064A \u0627\u0644\u0648\u0644\u0627\u064A\u0627\u062A \u0627\u0644\u0645\u062A\u062D\u062F\u0629 (\u0647\u0648 rVSV-ZEBOV) \u0641\u064A \u062F\u064A\u0633\u0645\u0628\u0631 2019. \u0648\u0627\u0633\u062A\u064F\u062E\u062F\u0645 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639 \u0623\u062B\u0646\u0627\u0621 \u062A\u0641\u0634\u064A \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627 \u0641\u064A \u0643\u064A\u0641\u0648 \u0628\u0645\u0648\u062C\u0628 \u0628\u0631\u0648\u062A\u0648\u0643\u0648\u0644 \u0627\u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0627\u0644\u0631\u062D\u064A\u0645. \u062E\u0644\u0627\u0644 \u0623\u0648\u0627\u0626\u0644 \u0627\u0644\u0642\u0631\u0646 \u0627\u0644\u062D\u0627\u062F\u064A \u0648\u0627\u0644\u0639\u0634\u0631\u064A\u0646\u060C \u0623\u0638\u0647\u0631 \u0627\u0644\u0639\u062F\u064A\u062F \u0645\u0646 \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0631\u0634\u062D\u0629 \u0641\u0639\u0627\u0644\u064A\u0629 \u0641\u064A \u0648\u0642\u0627\u064A\u0629 \u0627\u0644\u0631\u0626\u064A\u0633\u064A\u0627\u062A \u063A\u064A\u0631 \u0627\u0644\u0628\u0634\u0631\u064A\u0629 (\u0642\u0631\u0648\u062F \u0627\u0644\u0645\u0643\u0627\u0643 \u0639\u0627\u062F\u0629\u064B) \u0645\u0646 \u0627\u0644\u0639\u062F\u0648\u0649 \u0627\u0644\u0645\u0645\u064A\u062A\u0629."@ar . . . . . . "Rx-only"@en . . . . . "\u0644\u0642\u0627\u062D \u0627\u0644\u0625\u064A\u0628\u0648\u0644\u0627"@ar . . "Ebola-Impfstoff"@de . . . "Des vaccins contre le virus Ebola sont d\u00E9velopp\u00E9s depuis les ann\u00E9es 1980, mais leur emploi se heurte encore, quarante ans plus tard, \u00E0 diff\u00E9rents obstacles scientifiques et techniques."@fr . "viral"@en . . . . . .